MARY THORNTON: Open Payments
NPI 1073545042 · MCCOMB, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,585 in 119 payments from 16 companies in 2025. Trend: 2023 $1,949 · 2024 $1,832 · 2025 $2,585
Food & beverage: $2,501Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 42 | $619 |
| Janssen Biotech, Inc. | 21 | $475 |
| Madrigal Pharmaceuticals | 10 | $417 |
| GENZYME CORPORATION | 9 | $280 |
| Regeneron Healthcare Solutions, Inc. | 6 | $176 |
| Ardelyx, Inc. | 7 | $136 |
| QOL Medical, LLC | 5 | $125 |
| Aimmune Therapeutics, Inc. | 4 | $88 |
| Phathom Pharmaceuticals, Inc. | 5 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
Products named: TREMFYA, DUPIXENT, REZDIFFRA, RINVOQ, IBSRELA, CREON, Sucraid, LINZESS.
Industry payments across MS — which companies pay providers there.
